UBESLO

Serial Number 98726200
688

Registration Progress

Application Filed
Aug 30, 2024
Under Examination
Jun 24, 2025
Approved for Publication
Apr 29, 2025
Published for Opposition
Apr 29, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Dec 24, 2025 140 days

Trademark Image

UBESLO

Basic Information

Serial Number
98726200
Filing Date
August 30, 2024
Published for Opposition
April 29, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
Jun 24, 2025
Application
Pending
Classes
005

Rights Holder

NewAmsterdam Pharma B.V.

99
Address
Gooimeer 2 35
Naarden 1411DC
NL

Ownership History

NewAmsterdam Pharma B.V.

Original Applicant
99
Naarden NL

NewAmsterdam Pharma B.V.

Owner at Publication
99
Naarden NL

Legal Representation

Attorney
Michelle Rosenberg

USPTO Deadlines

Next Deadline
140 days remaining
NOA E-Mailed - SOU Required
Due Date
December 24, 2025
Extension Available
Until June 24, 2026

Application History

14 events
Date Code Type Description Documents
Jun 24, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 29, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 29, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 23, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 1, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 21, 2025 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 21, 2025 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Mar 21, 2025 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 8, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 8, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Mar 8, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 5, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 30, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Aug 30, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
pharmaceutical preparations for lowering cholesterol; pharmaceuticals, namely, lipid lowering agents; pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and disorders, major adverse cardiac events, cholesterol-related diseases and disorders, dyslipidemia, lipid-related diseases and disorders, diabetes, age-related macular degeneration, neurodegenerative diseases and disorders, dementia, Lewy body dementia, and Alzheimer's disease

Classification

International Classes
005